Evidence map›Paper›PMID 16636311›Full record

ArticleExperimental biology and medicine (Maywood, N.J.)2006

Retinoic acid exerts dual regulatory actions on the expression and nuclear localization of interferon regulatory factor-1.

Xin M Luo, A Catharine Ross

Abstract read
In one paragraph

Article in Experimental biology and medicine (Maywood, N.J.), 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
1.0field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 36 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Understanding the Action of RARγ Agonists on Human Osteochondroma Explants.International journal of molecular sciences · 2020
    Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Xin M LuoDepartment of Nutritional Sciences, 126-S Henderson Building, University Park, PA 16802, USA.
A Catharine Ross
Pennsylvania State University · US

Funding

VITAMIN A NUTRITIONAL STATUS AND IMMUNE FUNCTIONR01DK041479 · NIDDK · PENNSYLVANIA STATE UNIVERSITY-UNIV PARK · PI ROSS, A. CATHARINE · 1989 to 2015
$4.0M
Molecular Regulation of LRAT and CYP26 in Lung and LiverR01CA090214 · NCI · PENNSYLVANIA STATE UNIVERSITY-UNIV PARK · PI ROSS, A. CATHARINE · 2001 to 2012
$2.6M
Retinoid Nutritional Status and Immune FunctionR56DK041479 · NIDDK · PENNSYLVANIA STATE UNIVERSITY, THE · PI ROSS, A. CATHARINE · 2012 to 2012
$158k
NCI NIH HHS CA 90214NCI NIH HHS R01 CA090214NIDDK NIH HHS DK 41479NIDDK NIH HHS R01 DK041479NIDDK NIH HHS R56 DK041479
6 · The paper itself

Abstract

Interferon regulatory factor-1 (IRF-1), a transcription factor and tumor suppressor involved in cell growth regulation and immune responses, has been shown to be induced by all-trans retinoic acid (ATRA). However, the factors controlling the cellular location and activity of IRF-1 are not well understood. In this study, we examined the expression of IRF-1 and its nuclear localization, DNA-binding activity, and target gene expression in human mammary epithelial MCF10A cells, a model of breast epithelial cell differentiation and carcinogenesis. Following initial treatment with ATRA, IRF-1 mRNA and protein were induced within 2 hrs, reached a peak (>30-fold induction) at 8 hrs, and declined afterwards. IRF-1 protein was predominantly cytoplasmic during this treatment. Although a second dose of ATRA or Am580 (a related retinoid selective for retinoic acid receptor-alpha [RARalpha]), given 16 hrs after the first dose, restimulated IRF-1 mRNA and protein levels to a similar level to that obtained by the first dose, IRF-1 was predominantly concentrated in the nucleus after restimulation. ATRA and Am580 also increased nuclear RARalpha, whereas retinoid X receptor-alpha (RXRalpha)--a dimerization partner for RARalpha, was localized to the nucleus upon second exposure to ATRA. However, ATRA and Am580 did not regulate the expression or activation of signal transducer and activator of transcription-1 (STAT-1), a transcription factor capable of inducing the expression of IRF-1, indicating an STAT-1-independent mechanism of regulation by ATRA and Am580. The increase in nuclear IRF-1 after retinoid restimulation was accompanied by enhanced binding to an IRF-E DNA response element, and elevated expression of an IRF-1 target gene, 2',5'-oligoadenylate synthetase-2. The dual effect of retinoids in increasing IRF-1 mRNA and protein and in augmenting the nuclear localization of IRF-1 protein may be essential for maximizing the tumor suppressor activity and the immunosurveillance functions of IRF-1 in breast epithelial cells.

Indexed as

2',5'-Oligoadenylate SynthetaseAntineoplastic AgentsCell LineCell NucleusHumansInterferon Regulatory Factor-1Receptors, Retinoic AcidRetinoic Acid Receptor alphaRetinoid X Receptor alphaSTAT1 Transcription FactorTretinoin2',5'-Oligoadenylate SynthetaseAntineoplastic AgentsInterferon Regulatory Factor-1IRF1 protein, humanRARA protein, humanReceptors, Retinoic AcidRetinoic Acid Receptor alphaRetinoid X Receptor alphaSTAT1 protein, humanSTAT1 Transcription FactorTretinoin

Identifiers

PMID16636311
PMCPMC3843134
OpenAlexW1748998227

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.